Tuesday Night Rheumatology: Advances & Challenges in Lupus Care nitter.siddz.com/i/broadcasts/1XGygwWBy…

Novartis announced the European Commission has approved secukinumab (Cosentyx) for use in adults w/ polymyalgia rheumatica, not responding to GCs. SEC is 1st IL-17A inhibitor approved in Europe for PMR buff.ly/Nq6MNMT

JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory (failure 54.5% vs 78.5% placebo). Goal: remission with minimal steroids. buff.ly/u5R22zG

"We really need to ask every patient who has psoriasis about their joints” – Dr. Ahmad Amin, Dermatologist Watch Dr. Amin and Dr. Saakshi Khattri discuss the link between skin and joints in PsA. Sponsored by AbbVie Medical Affairs + Health Impact. buff.ly/gPoZNZp

Prof. Mease shares this important slide illustrating how excessive adipose tissue contributes to PsA dev’t 👇 Dysfunctional adipose tissue enables overall amplification of inflammation in obese pts with PsA @RheumNow #APLAR2026

Optimizing GC use in SLE: In arthritis, avoid oral GC - consider NSAIDS, csDMARDs, small molecules or biologics On GC initiation, hit hard w/pulse MP then taper early and rapidly In LN, treat aggressively bec damage is driven by dse activity, not meds @RheumNow #APLAR2026

OA injections span three tiers: symptom-modifying (steroid, HA, polynucleotides), structure-oriented (sprifermin, Wnt inhibitors) and biologic (PRP, MSCs, EVs). None looks far superior to steroid or HA for symptoms; structural benefit is the goal. OA SIG #APLAR26 @RheumNow

The @RheumNow crew together at #APLAR2026

T cell clone in AxSpA Trvb9 & Trav 21 B27 pos pts - t cell engager developed @RheumNow #APLAR2026

Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis. buff.ly/SjmfsZz

Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings Listen to leading rheumatology and dermatology experts for an engaging discussion on the evolving landscape of Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE). buff.ly/D4XlB93

ACR Convergence 2026 is almost here. Whether you’re attending in person or following from afar, RheumNow will bring you the research, clinical updates and expert insights you need to know. Join us for #ACR26 coverage beginning November 7th at RheumNow.com. #ACR26 #Rheumatology

The Efficacy of Ianalumab in Sjögren’s Disease The NEPTUNUS-1 and NEPTUNUS-2 trials have showed that monthly ianalumab is superior of placebo at improving Sjögren’s disease activity at week 48, even though there was no significant ESSDAI response or in the change in SSSD or ESSPRI symptom scores. buff.ly/lS9ydc5

Tx persistence & response in PsA is a problem - influenced by demographics & Dz severity. 815 PsA pts in e Brit Society Rheumatology PsA Registe. @12 mos - 24% MDA, 24% ACR50. Median F/U 31 mos, only 65% still on index Rx. D/C higher w/ PDE4i & poorer baseline activity & PROs buff.ly/ZTZueX8

🚨NOW IN THE POSTER HALL: Long-Term Safety of a JAKi in Clinical Trial and Real-World Settings Across >21,000 Patient-Years Check out the data in RA, PsA, AS, and nr-axSpA presented at EULAR 2026: buff.ly/tSBvPxB Sponsored by AbbVie Medical Affairs + Health Impact.

Patients with type 2 SLE present with fatigue, pain, brain fog and mood changes. Type 1 & 2 often coexist but type 2 SLE impacts QOL. @RheumNow #lupus #APLAR2026

Excites to report on #APLAR26 in Seoul, S. Korea for @RheumNow along with Drs. @RHEUMarampa and Peter Nash

24-Week Interim Findings from a Randomized Phase 2 Study of Iptacopan (LNP023) Indicate High Remission Rates in Participants with Active ANCA-Associated Vasculitis acrabstracts.org/abstract/24… and liver safety over time is?

CDR209: A Novel TRBV9×CD3 T Cell Engager for Precision Depletion of Disease-Associated T Cells in Axial Spondyloarthritis acrabstracts.org/abstract/cd… anti-TRVB and anti-TRAV for your B27 AxSpA patients ( and needs looking at B27 positive PsA ) watch this space

Schett : in vivo the future if it works, during LD aciclovir, co-trimoxazole, CAR-T expansion amount not associated with toxicity, 3 month no vaccination window, all tissues B cell depletion , naive b cells return APLAR Seoul 2026 #CART #RheumNow

number of naive-like CAR-T infused associates with prolonged survival but highly variable APLAR Seoul 2026 #CAR-T #Rheum Now